» Articles » PMID: 36506611

Modern Imaging Techniques for Monitoring Patients with Multiple Myeloma

Overview
Journal Med Pharm Rep
Specialty General Medicine
Date 2022 Dec 12
PMID 36506611
Authors
Affiliations
Soon will be listed here.
Abstract

Bone disease is a serious problem for many patients, often causing pathological bone fractures. A spinal collapse is a condition that affects the quality of life. It is the most frequent feature of multiple myeloma (MM), used in establishing the diagnosis and the need to start treatment. Because of these complications, imaging plays a vital role in the diagnosis and workup of myeloma patients. For many years, conventional radiography has been considered the gold standard for detecting bone lesions. The main reasons are the wide availability, low cost, the relatively low radiation dose and the ability of this imaging method to cover the entire bone system. Because of its incapacity to evaluate the response to therapy, more sophisticated techniques such as whole-body low-dose computed tomography (WBLDCT), whole-body magnetic resonance imaging, and 18F-fluorodeoxyglucose-positron emission tomography/computed tomography (PET/CT) are used. In this review, some of the advantages, indications and applications of the three techniques in managing patients with MM will be discussed. The European Myeloma Network guidelines have recommended WBLDCT as the imaging modality of choice for the initial assessment of MM-related lytic bone lesions. Magnetic resonance imaging is the gold-standard imaging modality for the detection of bone marrow involvement. One of the modern imaging methods and PET/CT can provide valuable prognostic data and is the preferred technique for assessing response to therapy.

Citing Articles

The numerous facets of 1q21 in multiple myeloma: Pathogenesis, clinicopathological features, prognosis and clinical progress (Review).

Liu N, Xie Z, Li H, Wang L Oncol Lett. 2024; 27(6):258.

PMID: 38646497 PMC: 11027100. DOI: 10.3892/ol.2024.14391.

References
1.
Barwick T, Bretsztajn L, Wallitt K, Amiras D, Rockall A, Messiou C . Imaging in myeloma with focus on advanced imaging techniques. Br J Radiol. 2019; 92(1095):20180768. PMC: 6540859. DOI: 10.1259/bjr.20180768. View

2.
Croft J, Riddell A, Koh D, Downey K, Blackledge M, Usher M . Inter-observer agreement of baseline whole body MRI in multiple myeloma. Cancer Imaging. 2020; 20(1):48. PMC: 7362571. DOI: 10.1186/s40644-020-00328-9. View

3.
Hillengass J, Merz M, Delorme S . Minimal residual disease in multiple myeloma: use of magnetic resonance imaging. Semin Hematol. 2018; 55(1):19-21. DOI: 10.1053/j.seminhematol.2018.02.001. View

4.
Karampinos D, Ruschke S, Dieckmeyer M, Diefenbach M, Franz D, Gersing A . Quantitative MRI and spectroscopy of bone marrow. J Magn Reson Imaging. 2017; 47(2):332-353. PMC: 5811907. DOI: 10.1002/jmri.25769. View

5.
Abe Y, Ikeda S, Kitadate A, Narita K, Kobayashi H, Miura D . Low hexokinase-2 expression-associated false-negative F-FDG PET/CT as a potential prognostic predictor in patients with multiple myeloma. Eur J Nucl Med Mol Imaging. 2019; 46(6):1345-1350. DOI: 10.1007/s00259-019-04312-9. View